About olaratumab
Monoclonal antibody; platelet-derived growth factor receptor alpha inhibitor
Used for
- Previously treated advanced soft-tissue sarcoma with doxorubicin, under restricted historical authorization
Usual adult dose
15 mg/kg by intravenous infusion on days 1 and 8 of each 21-day cycle, with doxorubicin.
Common side effects
- Infusion reactions
- Nausea
- Musculoskeletal pain
- Low blood cell counts
Important warnings
- Authorization was withdrawn after confirmatory trials showed no survival benefit; not recommended for new treatment.
- Serious infusion reactions can occur; monitor during and after infusion.
- Combination with doxorubicin increases risks of heart damage and bone-marrow suppression.
Pregnancy
May harm an unborn baby; pregnancy status should be checked before treatment.
Breastfeeding
Breastfeeding is not recommended during treatment and for three months after the final dose.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.